Baker Bros. Advisors LP Adc Therapeutics Sa Transaction History

Baker Bros. Advisors LP

  • $7.52 Billion
  • Q2 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 15, 2021
SELL
$20.45 - $30.0 $29 Million - $42.5 Million
-1,418,107 Closed
0 $0
Q4 2020

Feb 16, 2021
SELL
$25.26 - $38.02 $6.8 Million - $10.2 Million
-269,393 Reduced 15.96%
1,418,107 $45.4 Million
Q2 2020

Aug 14, 2020
BUY
$29.65 - $46.81 $50 Million - $79 Million
1,687,500 New
1,687,500 $79 Million

Others Institutions Holding ADCT

# of Institutions
79
Shares Held
52.9M
Call Options Held
300K
Put Options Held
59.3K
View Full List

About ADC Therapeutics SA

ADCT Quotes by TradingView
  • Ticker ADCT
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,645,296
  • Market Cap $239M
  • Description
  • ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...
More about ADCT
Track This Portfolio

Track Baker Bros. Advisors LP Portfolio

Follow Baker Bros. Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Baker Bros. Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Baker Bros. Advisors LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email